NTRA stock sentiment todayNatera, Inc.
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
NTRA
Natera, Inc.Dominant market share in NIPT and the massive MRD (Minimal Residual Disease) tailwind make Natera a premier growth story in diagnostics, despite premium valuation.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for NTRA. Not financial advice.
Price · last 12 months
Gossip
The narrative is centered on Natera's transition from a prenatal testing leader to an oncology powerhouse via its Signatera platform. Recent earnings beats and raised guidance have silenced skeptics regarding profitability timelines.
- ·Signatera adoption in oncology
- ·Favorable Medicare reimbursement updates (MolDX)
- ·High short-squeeze potential during earnings beats
- ·Legal victories in patent litigation against competitors
Financial
Revenue growth consistently exceeds 40% YoY. While historically loss-making due to high R&D, the company is trending toward cash-flow positivity and maintains a robust balance sheet with over $800M in cash.
- ·Revenue Growth: ~50% YoY
- ·Gross Margins: Expanding toward 60%+
- ·P/S Ratio: ~15x (Premium but justified by growth)
- ·Cash Runway: Significant, reduced burn rate
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·High sensitivity to changes in Medicare reimbursement rates
- ·Intense litigation environment in the genetic testing space
- ·Potential dilution from future convertible note conversions
Peer temperature
How direct competitors stack up against NTRA right now.
- NEUTRALEXASExact Sciences
COLDER — Slower growth profile as Cologuard matures compared to Natera’s rapid Signatera ramp-up.
See full analysis → - NEUTRALGHGuardant Health
COLDER — Facing stiffer competition in the liquid biopsy space and higher cash burn relative to Natera's path to profitability.
See full analysis → - COLDNEONeoGenomics
COLDEST — Struggling with lower margins and operational headwinds compared to Natera’s tech-driven scalability.
See full analysis →
- NTRA+19.5%
- EXAS—
- GH-1.1%
- NEO+10.5%
Analyst price target
Consensus average of 20 analysts · median 350.00
Source: StockAnalysis.com · updated 2026-09-08
AI-generated analysis for informational purposes only. Not financial advice.